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Metabolomic analysis of mouse 
prefrontal cortex reveals 
upregulated analytes during 
wakefulness compared to sleep
Allen K. Bourdon  1, Giovanna Maria Spano2, William Marshall2, Michele Bellesi2,7, 
Giulio Tononi2, Pier Andrea Serra3, Helen A. Baghdoyan  4,5, Ralph Lydic4,5, 
Shawn R. Campagna1,6 & Chiara Cirelli2
By identifying endogenous molecules in brain extracellular fluid metabolomics can provide insight 
into the regulatory mechanisms and functions of sleep. Here we studied how the cortical metabolome 
changes during sleep, sleep deprivation and spontaneous wakefulness. Mice were implanted with 
electrodes for chronic sleep/wake recording and with microdialysis probes targeting prefrontal and 
primary motor cortex. Metabolites were measured using ultra performance liquid chromatography-high 
resolution mass spectrometry. Sleep/wake changes in metabolites were evaluated using partial least 
squares discriminant analysis, linear mixed effects model analysis of variance, and machine-learning 
algorithms. More than 30 known metabolites were reliably detected in most samples. When used by 
a logistic regression classifier, the profile of these metabolites across sleep, spontaneous wake, and 
enforced wake was sufficient to assign mice to their correct experimental group (pair-wise) in 80–100% 
of cases. Eleven of these metabolites showed significantly higher levels in awake than in sleeping mice. 
Some changes extend previous findings (glutamate, homovanillic acid, lactate, pyruvate, tryptophan, 
uridine), while others are novel (D-gluconate, N-acetyl-beta-alanine, N-acetylglutamine, orotate, 
succinate/methylmalonate). The upregulation of the de novo pyrimidine pathway, gluconate shunt 
and aerobic glycolysis may reflect a wake-dependent need to promote the synthesis of many essential 
components, from nucleic acids to synaptic membranes.
Genome-wide transcriptomic studies have identified hundreds of mRNAs that show expression changes in neu-
rons and glia during sleep and wakefulness, independent of circadian time1–6. These studies have suggested new 
hypotheses about the restorative functions of sleep, from synaptic homeostasis to the synthesis of cellular compo-
nents and membranes3,4,7. Proteomic approaches also have been used to investigate functions of sleep, although 
applying proteomics to brain homogenates is difficult (e.g.8–12).
Metabolomics, or the study of the set of small-molecule metabolites within a biological system, is a powerful 
approach for identifying endogenous molecules in brain extracellular fluid. Untargeted metabolomics approaches 
not only detect molecules of known structure that can be identified from standard compounds, they also provide 
information on metabolites with undetermined structures and functions13. Because metabolomics provides func-
tional information about cellular physiology, measuring the brain metabolome may help to clarify how changes 
in neurochemistry contribute to the generation of sleep and wakefulness14. Moreover, metabolomics may provide 
insights about the functions of sleep. To date, metabolomic studies of sleep and wakefulness have used plasma and 
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urine samples that cannot directly inform about brain changes15–17 or brain homogenates that cannot distinguish 
between intracellular and extracellular metabolites18.
New detection methods are now available to analyze brain microdialysis samples with high sensitivity and 
specificity19–21. According to the human metabolome database, 440 compounds have been detected (quantified 
or not) in the cerebrospinal fluid22. How these metabolites relate to metabolites present in the brain extracellular 
fluid is unknown. The goal of the present study was to characterize changes in the composition of the extra-
cellular fluid that were associated with states of sleep and wakefulness, independent of circadian time or stress 
caused by sleep deprivation. Ultra performance liquid chromatography—high resolution mass spectrometry 
(UPLC-HRMS) was used to identify and quantify metabolites in mouse medial prefrontal cortex (mPFC) and pri-
mary motor cortex (M1). In vivo microdialysis was used to collect samples from mice during electrographically 
identified states of sleep and wakefulness during times when mice are normally asleep (light period), normally 
awake (dark period), and during sleep deprivation. We focused on mPFC and M1 because we recently found that 
whereas noradrenaline levels increased during waking and decreased during sleep in both regions, noradrenaline 
levels began declining by the end of 6 hours of sleep deprivation only in mPFC. This decline correlated with an 
increase in low (2–6 Hz) EEG frequencies, a marker of “fatigue”, suggesting that the build-up of sleep pressure 
during waking may occur faster in mPFC than in M123.
Results
Microdialysis samples were collected simultaneously in the mPFC and M1 brain regions of C57BL/6 J (B6) mice 
over approximately 10 hours in 15-min increments (41 time-points). There were 17 missing samples across all 
experimental conditions, resulting in a total of 1541 dialysate samples for analysis (Fig. 1a,b). Experiments were 
performed in three separate groups of animals, all of which were well entrained to the light/dark cycle. All mice 
spent the first 2 hours awake, slowly moving on a treadmill, and dialysate samples from the end of the first hour 
and the entire second hour (5 time-points total) were used as reference. Mice were then studied during the fol-
lowing 9 hours in different sleep/wake conditions (Fig. 1c,d). The first 2 groups were studied during the light 
Figure 1. Experimental design. (a) Schematic diagram showing the placement of the microdialysis probes, 
EEG electrodes and EMG wires; (b) set-up for EEG recording and microdialysis; (c) the 3 experimental groups. 
(d) mean % of wakefulness for each group in 15-min intervals. The 5 time-points in black refer to the end of the 
first hour and the entire second hour spent by the mice on the treadmill and used as reference (Ref). Blue time 
points indicate the periods when mice had the opportunity to sleep. Time points in red indicate the period of 
enforced wakefulness using novel objects. Time points in green show when mice were either spontaneous awake 
at night or placed on the treadmill for the last 3 hours of the experiment.
www.nature.com/scientificreports/
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phase, one group during a sustained period (~6 hours) of sleep followed by 3 hours of enforced wakefulness on 
the treadmill (S6-EW3), and the other group during 6 hours of wakefulness enforced by exposure to novel objects, 
followed by 3 hours of sleep (EW6-S3). Thus, these two groups of animals were studied at the same time of day 
and in the same lighting conditions (lights on) but on average, they spent most of last 9 hours of the experiment in 
opposite behavioral states (sleep or wake; Fig. 1d). The third group of mice was studied at the opposite circadian 
time, during the dark phase, and spent the last 9 hours mostly awake, the first 6 hours in their cages, and the last 
3 hours on the treadmill (SW6-EW3). The combination of these three groups, including enforced wakefulness 
during the day and spontaneous wakefulness at night, allowed us to assess the effects of sleep and wakefulness 
independent of possible confounding factors due to time of day, light exposure, and stimulation (novel objects) 
used to enforce wakefulness during the day, when mice would spontaneously sleep. From the mPFC and M1, 
respectively, of each experimental group, the following number of microdialysis samples were collected; 281 and 
278 from Group S6-EW3 (n = 7 mice), 246 and 246 from Group EW6-S3 (n = 6), and 244 and 246 from Group 
SW6-EW3 (n = 6). Following collection, a 10 µL injection of each sample was analyzed by an untargeted metabo-
lomics method using UPLC-HRMS. The time course plots (Fig. 1d) indicate the average amount of time that mice 
actually spent awake or asleep during the different treatment conditions.
Heatmap Analysis. First, known metabolites were compared in a pairwise fashion between treatment 
groups using changes in z-score of metabolite intensities as a proxy for relative metabolite concentrations. To 
visualize these data during the first 6 hours of sleep or wake (S6, EW6, SW6), heatmaps24 were constructed that 
compared metabolite levels across each possible pair of experimental groups in mPFC and separately in M1 (S6 
vs. EW6, S6 vs SW6, EW6 vs SW6). This visualization, shown in Fig. 2, conserves the hour-by-hour sampling 
provided by in vivo microdialysis, allowing the identification of metabolic trends between treatment conditions. 
For example the increases in pyruvate, lactate, orodate, uridine, gluconate, and glutamate during spontaneous 
wakefulness and/or enforced wakefulness relative to sleep that are described below can be visualized in the heat 
maps by the presence of more red and/or green cells in the rows corresponding to those analytes.
Results of LME Models. To promote generalizability of the results, statistical analysis was restricted to 
metabolites that were observed at least in 3 mice per treatment condition. This selection criterion was applied 
separately to each brain region and provided a list of 33 known metabolites common to both mPFC and M1, and 
3 metabolites that were unique to mPFC (36 metabolites total; see Methods for details). Three linear mixed effect 
models were applied to each metabolite. The first model focused on the first 6 hours, and the levels of each com-
pound were compared “across groups” of mice that spent most of that time in different behavioral states, either 
sleep, or enforced wakefulness or spontaneous wakefulness (S6, EW6, SW6). The other two models were “within 
group” models, i.e. they compared the levels of each metabolite during 9 consecutive hours in the same mouse, 
either during spontaneous sleep followed by enforced wakefulness (S6-EW3), or during enforced wakefulness 
followed by spontaneous sleep (EW6-S3). To be considered as state-specific, a known metabolite (or unidentified 
Figure 2. Heatmap analysis. Graphical representation of changes in metabolite levels between microdialysis 
samples collected from mPFC and M1 expressed as changes in Z score. Each cell represents a 1-hour coarse-
grained average ion intensity across the first 6 hours of spontaneous sleep (S6), enforced wakefulness (EW6) 
or spontaneous wakefulness (SW6). Group comparisons are indicated above each panel. Metabolites (listed at 
left) are organized by metabolic pathway (listed at right) and listed in bold text when the differences between 
behavioral states were subsequently identified as statistically significant (LME models). Heatmaps were 
generated in R with the ggplot2 and colorspace packages.
www.nature.com/scientificreports/
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spectral features, see below) was required to meet the following criteria: 1) show a statistically significant change 
in at least one model (p < 0.05); and 2) show biologically consistent changes in the other models, even if those 
changes did not reach significance. For example, a compound that showed a significant increase in the wake 
groups (SW6, EW6) relative to the sleep group (S6) but no increase in the same mouse during the wake period 
after sleep (S6-EW3) and no decline in the same mouse during the sleep period after wakefulness (EW6-S3) was 
not considered “state-specific”.
Table 1 lists the 11 known metabolites that showed changes with sleep and wakefulness according to these 
strict criteria. These 11 metabolites represented approximately 30% of the metabolites consistently detected in our 
samples (33 in M1, 36 in mPFC). All of the 11 analytes reported in Table 1 decreased throughout the sleep period 
relative to both wake conditions (Figs 3 and 4). Among the 33 comparisons presented, in 31 we identified a signif-
icant behavioral state * time interaction, with the differences between behavioral states being more pronounced 
at the end of the experiment than at the beginning. For the remaining 2 comparisons, the differences between the 
sleep and wake conditions were consistent for the duration of the experiments (Table 1). One analyte (homovan-
illic acid) showed a significant condition by brain region interaction, with state-specific changes occurring pri-
marily in mPFC. Several other metabolites, including homoserine/threonine, uracil, and valine, showed highly 
significant temporal effects in all three behavioral states, with levels decreasing from hour 1 to hour 9. This profile 
likely reflects some form of “depletion” during prolonged sampling, and these analytes are not further discussed.
We then tested whether changes in the levels of these 11 metabolites were correlated with changes in the EEG 
power spectrum. The analyses focused on low frequency (2–6 Hz) activity during wakefulness and slow wave 
activity (SWA, 0.5–4 Hz) during NREM sleep, two markers of sleep pressure that increase during sleep depriva-
tion and subsequent recovery sleep, respectively23. Consistent with previous findings in humans and rodents, low 
frequency activity increased significantly across the course of the 6 hours of sleep deprivation (EW6, Fig. 5 inset). 
This increase correlated negatively with the increase of tryptophan and uridine in mPFC, and of tryptophan in 
M1 (after correcting for multiple comparisons; Fig. 5, Table 2). Succinate/Methylmalonate was the only metabo-
lite positively correlated with 2–6 Hz activity, and only in mPFC (Fig. 5, Table 2).
As expected SWA was high at sleep onset and declined significantly in the course of recovery sleep following 
sleep deprivation (Fig. 6 inset). For most metabolites the decline during sleep was positively correlated with the 
decline in SWA, especially in mPFC (Fig. 6, Table 2). There were no correlations with gamma activity (40–100 Hz) 
during wake (not shown).
An additional LME model was used to compare the concentration of metabolites during 3 different sleep 
periods: “early sleep” and “late sleep” were defined as the first 3 and the last 3 hours of the S6 experiment, respec-
tively, and “recovery” indicated the 3 hours of recovery sleep after the EW6 experiment (see Methods for details). 
Specifically, we asked whether the trend for a metabolite concentration to decrease was different among early, late 
and recovery sleep. The results are summarized in Table 3 and demonstrated a significant interaction between 
sleep condition and time in all compounds and typically in both regions, with two exceptions (pyruvate in mPFC 
and glutamate in M1). Other than succinate, all significant interactions followed the same general pattern, with 
metabolite concentration decreasing faster during early sleep and recovery sleep than during late sleep, consistent 
with higher sleep pressure in the first two conditions. To further distinguish early sleep from recovery sleep we 
then performed post-hoc tests to classify each interaction into one of 3 possibilities, depending on whether the 
rate of concentration decrease did not differ between early sleep and recovery sleep (type 1), was faster in recovery 
sleep than in early sleep (type 2), or vice versa (type 3). For only 2 metabolites, glutamate and lactate, the concen-
tration decreased faster during recovery sleep than during early sleep.
Finally, 17 of the unidentified spectral features of the UPLC-HRMS spectra were reliably detected in the 
majority of animals in each of the 3 experimental groups and changed with sleep and wakefulness according to 
the same strict criteria discussed above for the known metabolites, including 16 that were increased in wake and 
Metabolite
Between Groups
(S6-SW6-EW6)
Within Group 
(S6-EW3)
Within Group 
(EW6-S3)
D-Gluconate 0.0032(**) 0.0007(***) 0.1291
Glutamate 0.0253(*) 0.0965 0.0037(**)
Homovanillic acid 0.0051(**) 0.0125(*) 0.0000(***)
Lactate 0.0020(**) 0.0386(*) 0.0000(***)
N-acetyl-beta-alanine 0.0013(**) 0.0264(*) 0.0169(*)
N-acetyl-glutamine 0.0894 0.0336(*) 0.0554
Orotate 0.1067 0.0006(***) 0.0057(**)
Pyruvate 0.8409 0.0012(**) 0.0040(**)
Succinate/Methylmalonate 0.0000(***) 0.2814 0.3415
Tryptophan 0.4869 0.0000(***) 0.4829
Uridine 0.0363(*) 0.0000(***) 0.6407
Table 1. Significance levels of the 11 known metabolites with consistent differences between behavioral states. 
The p-values generally reflect a behavioral state by time interaction, with the sleep conditions decreasing while 
the wake conditions remained constant (or increase). Pyruvate (S6-SW6-EW6) and orotate (S6-EW3) were the 
only two exceptions, in that the reported p-values represent a main effect of state and no time interaction).  
(*)p < 0.05, (**)p < 0.01, (***)p < 0.001. Abbreviations: S, sleep; SW, spontaneous wakefulness; EW, enforced 
wakefulness.
www.nature.com/scientificreports/
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1 that was increased in sleep. Table 4 provides the mass and retention times for these unknown features as well as 
the results of the statistical analyses.
Classification Analyses. Partial least squares discriminant analyses (PLSDA) were used to deter-
mine whether the metabolic profiles during the first 6 hours of sleep, enforced wakefulness, and spontaneous 
Figure 3. Time course of z-score changes for the 11 metabolites with significant and consistent differences 
between behavioral states in mPFC (mean ± sem). In each plot the vertical line indicates a behavioral state 
transition at hour 6 (e.g, from S6 to EW3). Typically, the levels of these metabolites were decreasing during 
sleep, and either increasing or constant during the two wakefulness conditions. Abbreviations: mPRF (medial 
prefrontal cortex); SW, spontaneous wake; EW enforced wake; S, spontaneous sleep.
www.nature.com/scientificreports/
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wakefulness could distinguish between the 3 behavioral states. All known metabolites consistently detected in 
our samples (33 in M1, 36 in mPFC) were used for this analysis. PLSDA is a commonly used statistical approach 
in metabolomics because it is properly suited for an uneven design matrix, in which the number of depend-
ent variables (detected metabolites) is larger than the number of independent variables (number of samples). 
Figure 4. Time course of z-scored changes for the 11 metabolites with significant and consistent differences 
between behavioral states in M1 (mean ± sem). In each plot the vertical line indicates a behavioral state 
transition at hour 6. Similar to mPFC, metabolite levels tended to decrease during sleep, and either increased 
or remained constant during the two wakefulness conditions. Abbreviations: M1, primary motor cortex; SW, 
spontaneous wake; EW, enforced wake; S, spontaneous sleep.
www.nature.com/scientificreports/
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Indeed, the metabolite profile from all 3 experimental groups (S6, EW6, SW6) was sufficient to classify the state 
of arousal using data from both mPFC and M1. The PLSDA model perfectly classified the mice into their respec-
tive experimental conditions. As shown in Fig. 7a plotting the PLSDA score values of PLS Component 1 and 
PLS Component 2 demonstrated visible clustering and clear separation between the 3 experimental groups. 
Additionally, PLSDA identified the metabolites that drive the separation among conditions by ascribing a variable 
importance of projection score (VIP). As the weighted sum of the squared correlations between PLSDA compo-
nents and the original variables, these values represent the percentage of variation explained by the component in 
the model. Generally, a VIP greater than 1.0 is considered most significant (i.e., metabolites with VIP >1 strongly 
contribute to the observed differences among groups). The 15 metabolites with the highest VIP scores are listed 
in Fig. 7a’ (mPFC) and 7a” (M1).
With so many explanatory variables and a relatively small number of mice, overfitting the PLSDA model was 
a concern. To better understand how the results will generalize, a K-fold stratified cross-validation procedure was 
used to estimate the accuracy of the classifier and statistical significance was assessed using non-parametric per-
mutations tests. The cross-validation analysis resulted in an estimated accuracy of 76.4%, which was significantly 
greater than chance (p < 0.05). We then explored alternative classification models to see if we could improve on 
the accuracy of PLSDA. The best accuracy was achieved using a logistic regression classifier with an ℓ2 regu-
larization penalty with sparsity parameter C = 0.001 (smaller values of C restrict the model and promote more 
sparsity). For this classifier the cross-validation procedure resulted in an estimated accuracy of 83%, which was 
Figure 5. Correlations between levels of each compound (log transformed; y axis) and 2–6 Hz EEG activity 
during wakefulness (x axis). Data and regression lines are depicted in green for mPFC and red for M1. The inset 
(bottom right) shows the averaged time course (n = 6 mice) of 2–6 Hz activity during the EW6-S3 experiment. 
Note the progressive increase in 2–6 Hz activity in the course of EW. Abbreviations: mPFC, medial prefrontal 
cortex; M1, primary motor cortex; EW, enforced wakefulness; S, sleep.
www.nature.com/scientificreports/
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Metabolite
2–6 Hz activity SWA (0.5–4 Hz)
mPFC M1 mPFC M1
r p p r p r p
D-gluconate 0.1205 0.5748 −0.0951 0.6584 0.4403 0.1520 0.4396 0.1527
Glutamate 0.3861 0.0624 −0.2459 0.2468 0.8016 0.0017 0.4535 0.1387
Homovanillic Acid 0.2153 0.3124 −0.2152 0.3125 0.6874 0.0135 0.6839 0.0142
Lactate −0.0657 0.7605 −0.2680 0.2054 0.8380 0.0007 0.6731 0.0164
N-acetyl-beta-alanine −0.2293 0.2812 −0.3562 0.0875 0.8273 0.0009 0.6522 0.0215
N-acetyl-glutamine −0.3561 0.0877 −0.4672 0.0213 0.3647 0.2437 0.7362 0.0063
Orotate 0.4405 0.0312 0.3337 0.1110 0.6318 0.0275 0.4993 0.0984
Pyruvate −0.0726 0.7362 −0.2643 0.2121 0.8331 0.0008 0.6877 0.0134
Succinate/Methylmalonate 0.6722 0.0003 0.2451 0.2483 0.6908 0.0129 −0.3926 0.2069
Tryptophan −0.6818 0.0002 −0.7175 0.0001 0.7250 0.0076 0.8837 0.0001
Uridine −0.6602 0.0004 −0.4474 0.0284 0.6901 0.0130 0.5192 0.0837
Table 2. Pearson’s coefficients and p-values between log-values for levels of each compound and 2–6 Hz activity or 
SWA. Values in bold are the ones surviving the correction for multiple comparison (Benjamini-Hochberg, 1995).
Figure 6. Correlations between levels of each compound (log transformed; y axis) and SWA during recovery 
sleep (x axis). Data and regression lines are depicted in green for mPFC and red for M1. The inset (bottom 
right) shows the averaged SWA time course (n = 6 mice) during the EW6-S3 experiment. Note the progressive 
SWA decline in the course of the 3 hours of recovery sleep (hours 6–9). Abbreviations: mPFC, medial prefrontal 
cortex; M1, primary motor cortex; SWA, slow wave activity; EW, enforced wakefulness; S, sleep.
www.nature.com/scientificreports/
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Metabolite Region p-value Pattern
D-Gluconate
mPFC 0.0385(*) Type1
M1 0.0007(***) Type3
Glutamate
mPFC 0.005(**) Type2
M1 0.754
Homovanillic Acid
mPFC 1.7e-8(***) Type3
M1 8.7e-15(***) Type3
Lactate
mPFC 2.9e-6(***) Type2
M1 7.8e-5(***) Type2
N-Acetyl-beta-alanine
mPFC 2.0e-5(***) Type1
M1 0.0001(***) Type3
N-Acetylglutamine
mPFC 0.007(**) Type1
M1 1.5e-6(***) Type3
Orotate
mPFC 1.2e-5(***) Type1
M1 0.003(**) Type1
Pyruvate
mPFC 0.2527
M1 0.002(**) Type1
Succinate/Methylmalonate
mPFC 0.025(*) other
M1 0.018(*) other
Tryptophan
mPFC 4.8e-5(***) Type3
M1 5.3e-8(***) Type3
Uridine
mPFC 0.0014(**) Type3
M1 0.0007(***) Type1
Table 3. Comparisons between early and late periods of spontaneous sleep and recovery sleep. Significance of 
condition * time interaction for each of the 11 significant compounds, in each region. For this analysis Time 
is a continuous covariate (linear). Condition is either “Early” (the first 3 hours of the S6 condition), “Late” (the 
last 3 hours of the S6 experiment) or Recovery (the 3 hours of sleep from the EW6-S3 experiment). Type 1: no 
significant difference between the conditions; Type 2: recovery sleep decreases significantly faster than early sleep; 
Type 3: early sleep decreases significantly faster than recovery sleep. (*)p < 0.05, (**)p < 0.01, (***)p < 0.001.
Mass
Retention 
Time
Between Groups
(S6-SW6-EW6)
Within Group
(S6-EW3)
Within Group 
(EW6-S3)
146.96404 8.24 0.1150 0.0030(**) 0.0000(***)
173.00636 5.35 0.0104(*) 0.0000(***) 0.0387(*)
263.04372 3.74 0.7308 0.0022(**) 0.0171(*)
90.02694 6.49 0.1210 0.0000(***) 0.0002(***)
125.00052 6.46 0.0004(***) 0.0000(***) 0.1352
169.01140 8.22 0.0284(*) 0.0710 0.0022(**)
88.01126 8.26 0.0352(*) 0.0497(*) 0.0000(***)
89.02361 1.21 0.0231(*) 0.6241 0.1312
126.99327 6.59 0.0074(**) 0.0110(*) 0.0118(*)
87.20528 5.19 0.0010(**) 0.0365(*) 0.0437(*)
244.99770 8.25 0.0011(**) 0.0037(**) 0.0000(***)
157.01139 5.31 0.0012(**) 0.0000(***) 0.0414(*)
206.01253 12.07 0.5829 0.9685 0.0000(***)
203.93613 12.72 0.1758 0.0250(*) 0.0000(***)
209.02997 5.27 0.0236(*) 0.0004(***) 0.0017(**)
473.07362 1.17 0.0001(***) 0.0014(**) 0.0050(**)
135.02959 12.69 0.0069(**) 0.0006(***) 0.0000(***)
Table 4. Significance levels of 17 unknown features with consistent differences between behavioral states 
(p-values). The p-values generally reflect either a behavioral state by time interaction, with the levels generally 
decreasing in the sleep conditions and the levels remaining constant or increasing during the wakefulness 
conditions, or a main effect of behavioral state with lower values during sleep than the wake conditions. One 
exception is the features with mass of approximately 473, which displayed a spike at the onset of sleep that then 
decayed over time back to baseline levels. (*)p < 0.05, (**)p < 0.01, (***)p < 0.001.
www.nature.com/scientificreports/
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significantly greater than chance (p < 0.001). Further exploring the ability for this classifier to pair-wise discrimi-
nate between conditions, we found that the sleep condition was distinguished from the two wake conditions with 
greater accuracy (S6 vs. SW6 accuracy 91.8%, p < 0.01; S6 vs. EW6 accuracy 100%, p < 0.01) than the two wake 
conditions could be distinguished from each other (SW6 vs. EW6 accuracy 82.1%, p = 0.003; Fig. 7b). This is 
consistent with the visualization of the PLSDA model (Fig. 7a), in which the clusters corresponding to the 2 wake 
conditions are closer to each other than they are to the sleep cluster.
Finally, we performed metabolite set enrichment analysis (MSEA;25) using the 11 metabolites identified as 
differentially expressed between sleep and wake, as well as the entire set of 37 metabolites expressed in most mice 
in at least one brain area (36 peaks, corresponding to 37 metabolites because succinate/methylmalonate could 
not be resolved in two separate peaks). The majority of the enriched pathways (>2-fold enrichment, in all cases 
p < 0.05) were identified using either 37 or 11 metabolites, although some differences were also present (Fig. 7c).
Discussion
Many previous microdialysis studies measured neurotransmitters, neuropeptides and select metabolites in the 
rodent brain across the sleep/wake cycle. In some experiments the high temporal resolution of biosensors was 
used to detect rapid changes in cortical levels of glutamate, lactate and glucose during wakefulness, NREM sleep 
and REM sleep26–30. In these reports, however, one or at most a few analytes were measured31,32. A recent study 
applied liquid chromatography and online mass spectrometry to the mouse prefrontal cortex to test a metabolo-
mics platform of almost 300 metabolites, of which approximately 120 were identified in the extracellular fluid33, 
but sleep/wake changes were not studied. Thus, to our knowledge, this is the first study providing a broader view 
of metabolome changes in the cortical extracellular space across the sleep/wake cycle and after sleep deprivation.
More than 30 small molecules in more than 80% of mice were identified. According to the LME model analy-
sis, 11 of these known metabolites were present at significantly higher levels after wakefulness, in most cases after 
both spontaneous and enforced wakefulness and in both cortical regions, while no metabolite was detected at 
higher levels after sleep. A similar trend was present among the differentially regulated unidentified spectral fea-
tures, with 16 upregulated in wakefulness and 1 in sleep. This “imbalance” between wake-related and sleep-related 
compounds is not new. Among the hundreds of transcripts modulated by sleep and wakefulness in neurons, 
astrocytes, and oligodendrocytes of rat and mouse cortex, the majority were transcripts whose expression was 
higher in both spontaneous and enforced wakefulness than in sleep1,6, reflecting either increased transcription 
Figure 7. PLSDA and associated VIP classification model. By combining the mPFC and M1 analyses, data 
from S6, EW6, and SW6 were used in the PLSDA to determine the overall variation between treatment 
conditions. (a) PLSDA plot showing significant separation of EW6 from S6 and SW6 in Component 1, and 
additional separation of S6 from SW6 and EW6 in Component 2. Each symbol indicates data from one 
mouse. Ellipses represent a confidence interval of 95%. VIP score plots for mPFC (a’) and M1 (a”), showing 
the 15 metabolites with the highest VIP scores. The bold text indicates the metabolites identified by LME 
analyses. (b) Classification accuracy of the logistic regression with ℓ2 regularization penalty. Error bars 
represent a non-parametric 95% confidence interval for the true accuracy estimated from the cross-validation 
data. The lower end of the confidence interval is above the chance line (dashed line) for all 4 comparisons. 
Abbreviations: mPFC, medial prefrontal cortex; M1, primary motor cortex; S, sleep; EW, enforced wakefulness; 
SW, spontaneous wakefulness; PLSDA (partial least squares discriminate analyses; VIP, variable importance 
of projection; LME, linear mixed effects. (c) Metabolite set enrichment analysis using the 11 metabolites 
differentially expressed between sleep and wake (left) and all 37 metabolites (right). Pathways with >2-fold 
enrichment (all p < 0.05) are shown.
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and/or decreased degradation of mRNAs during waking. In the current study, higher wake levels of analytes 
could reflect increased synthesis, decreased utilization, and/or decreased elimination by the glymphatic system 
that drives exchange of interstitial fluid with cerebrospinal fluid34,35. Wake-related metabolites reflect different 
signaling pathways and cellular processes and many, but not all, were already known to be differentially expressed 
across behavioral states. The potential relevance of each metabolite to states of sleep and wakefulness is briefly 
considered below.
Two energy metabolites were upregulated in wake relative to sleep, lactate and pyruvate, consistent with pre-
vious studies in rats and mice27,28,36–38. Astrocytes have strong glycolytic activity and produce lactate from glucose 
and glycogen via aerobic glycolysis while neurons, which have high oxidative capacity, mainly convert lactate into 
pyruvate to be used in the tricarboxylic acid cycle in the mitochondria39. Excitatory glutamatergic activity, which 
is higher in wakefulness than in sleep26, leads to increased astrocytic uptake of glucose, followed by an increase 
in the production of lactate, its release in the extracellular space, and uptake by neurons39. However, neurons can 
also directly uptake glucose and do not rely exclusively on astrocytes to produce pyruvate39,40. Thus, why astro-
cytes should release more lactate in response to neuronal activation is not obvious, at least if one assumes that 
lactate acts mainly as an energy substrate. On the other hand, aerobic glycolysis is stimulated in conditions of syn-
aptic growth, is blocked by inhibition of the noradrenergic system41, and lactate released from astrocytes excites 
locus coeruleus neurons and increases the release of noradrenaline42. Lactate may also serve as a volume trans-
mitter and the G protein coupled lactate receptor GPR81 is concentrated in the synaptic membranes of excitatory 
synapses43. Thus, lactate upregulation during wake may reflect increased synaptic growth and potentiation more 
than increased energy demand39,44. The latter could be met via increases in oxidative phosphorylation, and indeed 
mitochondrial enzymes of the respiratory chain are upregulated during waking45. Of note, the sleep-related drop 
in lactate levels was faster during recovery sleep than during early spontaneous sleep, and correlated with the 
decline in SWA, consistent with previous findings27. Overall, these results suggest that the regulation of sleep need 
may be linked to glycolytic processes46 and astrocytic functions47–49.
The gluconate shunt is a less known metabolic pathway that can facilitate the breakdown of glucose. It has been 
studied mainly in plants and microorganisms but key enzymes of the shunt, glucose dehydrogenase and gluconate 
kinase, have been identified in mammals50. In this pathway glucose is oxidized by glucose dehydrogenase to glu-
conic acid (or gluconate). Gluconate is then phosphorylated by gluconate kinase to produce 6-phosphogluconate, 
the second intermediate of the pentose phosphate pathway, thus bypassing the first rate-limiting step of this 
pathway51. The main function of the pentose phosphate shunt is anabolic rather than catabolic, producing pentose 
sugars for the synthesis of nucleic acids and amino acids. Thus, the increase in gluconate levels during wakeful-
ness may signal the need for growth, rather than for energy.
The de novo pyrimidine pathway provides critical components for the synthesis of DNA, RNA, sugars, gly-
cogen as well as phosphatidylcholine and phosphatidylethanolamine, the major phospholipids of the cellular 
membranes52,53. The levels of two intermediates in this pathway, orotate and uridine, were upregulated with wake-
fulness. Previous studies also found increased extracellular uridine content after neuronal depolarization54. Most 
uridine in the brain comes from the plasma. However, all genes responsible for the synthesis of pyrimidines 
are expressed at high levels in the cerebral cortex and other brain regions52, suggesting that the brain’s need for 
pyrimidines may be met also by in situ production. After its uptake by neurons and glia, uridine can be phospho-
rylated to UTP to serve as precursor for RNA and DNA synthesis, or it can be degraded glycolitically to maintain 
ATP levels55. UTP is also released in the extracellular space where is converted back to uridine or has neuro-
trophic effects after binding P2Y receptors54. Uridine also promotes neurite outgrowth and spinogenesis, but 
whether these effects depend on a specific “uridine receptor” remains unclear54,56. Thus, like lactate and gluconate, 
increased orotate and uridine levels during wakefulness may signal the need for the synthesis of many essential 
components, from nucleic acids to cellular and synaptic membranes. Of note, uridine was one of the active com-
ponents of the sleep promoting substance purified from the brainstem of sleep deprived rats, and intracerebral 
infusion of uridine promotes sleep56, suggesting that extracellular high uridine levels may reflect increased sleep 
need. Consistent with this idea, the decline of uridine levels during recovery sleep was correlated with the SWA 
decline. Intriguingly, the increase of uridine in the course of 6 hours of sleep deprivation was negatively, rather 
than positively, correlated with the 2–6 Hz EEG activity. This negative correlation was strongest in mPFC but 
present also in M1. In both humans and rodents the increase in low frequency activity during extended wake 
reflects the tendency of some cortical neurons to stop firing and go “off line”, as during NREM sleep57,58. Thus, we 
speculate that uridine levels reflect sustained firing of cortical neurons.
Succinate/Methylmalonate could not be resolved in separate peaks. Succinate is an intermediate of the tricar-
boxylic acid cycle and methylmalonate (MMA) is converted to succinyl coenzyme-A by an enzymatic reaction 
that uses vitamin B12 (cobalamin) as a cofactor. High levels of MMA, due to vitamin B12 deficiency or some 
genetic disorders, can inhibit the activity of the mitochondrial respiratory chain complex by interfering with the 
mitochondrial uptake of succinate59,60. Elevated serum MMA levels have been reported in patients with idiopathic 
Parkinson’s disease and may be one of the biomarkers for this pathology61.
The wake-related increase in extracellular levels of glutamate confirms and extends previous findings in rat26 
and mouse28 cerebral cortex, and is consistent with overall increased glutamatergic neurotransmission during 
wakefulness relative to sleep. The state-specific changes in glutamate measured here also are consistent with evi-
dence that glutamate in pontine reticular formation of rat also decreases during sleep21. Moreover, we found that 
the progressive decrease in cortical glutamate concentration was faster during recovery sleep than during early 
spontaneous sleep, consistent with previous evidence that the sleep-dependent decline of glutamate correlates 
with SWA26. As for lactate, this result suggests that the rate of glutamate changes may reflect sleep pressure, 
although circadian time, the stimulation used to enforce wake, or the “exercise” on the moving wheel during 
baseline may have contributed to the difference between spontaneous sleep and sleep following sleep deprivation.
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Two other metabolites upregulated during wakefulness, homovanillic acid (HVA) and tryptophan, reflect the 
activity of well-known groups of wake-active neurons. HVA is one of the major dopamine (DA) metabolites and 
a valid indicator of DA turnover. DA extracellular levels in the mPFC are increased by novelty and higher during 
wakefulness than during sleep31,62, consistent with the fact that DA neurons in the ventral tegmental area, which 
project to mPFC, are more active during wakefulness than during sleep and promote arousal63,64. Tryptophan is 
an essential amino acid and the precursor of the neurotransmitter serotonin. Like DA neurons in the VTA, sero-
tonin neurons in the dorsal raphe are more active during wakefulness than during sleep and extracellular levels of 
serotonin are higher in wakefulness than in sleep in different brain regions, including prefrontal cortex65.
N-Acetyl-beta-alanine is an endogenous β amino acid that can be converted to acetate and β alanine by 
N-acetyl-β alanine dehydrogenase66. β-alanine is a molecular intermediary of GABA and glycine with a very 
similar mechanism of action, and is considered an inhibitor neurotransmitter67. In the brain, however, the best 
characterized pathway leading to β-alanine synthesis is the deamination and carboxylation of the pyrimidine 
uracil68,69, while very little is known about N-acetyl-β alanine dehydrogenase. Thus, the functional significance 
of the upregulation of N-acetyl-beta-alanine during wakefulness remains unclear. Similarly, very little is known 
about changes in the levels of N-acetylglutamine, the acetylated analogue of glutamine, one of the main amino 
acids used in protein synthesis and an essential constituent of the diet.
To our knowledge, these data provide the initial measures of the metabolome in the extracellular space of 
B6 mice across the sleep/wake cycle and after sleep deprivation. The finding that many of these molecules vary 
significantly as a function of sleep and wakefulness is consistent with the interpretation that these molecules are 
lower-level phenotypes contributing to the regulation of EEG and behavioral levels of arousal. Another not mutu-
ally exclusive interpretation is that at least some of the state-specific changes in brain metabolome are correlates 
of changes in behavioral states. Causal experiments will be needed to distinguish between these possibilities. 
Untargeted and targeted metabolomic approaches are being used to help clarify anesthesia-induced alterations 
in brain chemistry21. Acknowledged challenges for metabolomic approaches include analyses and interpretation 
of large and complex datasets, exemplified in the present study by the measurement of 33 analytes common to 
both mPFC and M1 brain regions. Analytic issues include the fact that metabolomic data violate the assumption 
of independence assumed by the general linear model. Finally, the present data are limited to the cerebral cor-
tex. As metabolomic approaches become more widely used, it will be possible to build conceptual models that 
incorporate data regarding chemical networks across brain regions. These and other limitations are offset by the 
fact that metabolomic approaches, even in this early stage of application to studies of sleep, offer more complete 
insights than do measures of a single analyte. Medications used to modulate levels of arousal alter the entire 
chemical milieu of the central nervous system, not merely a single neurotransmitter. Future use of metabolomic 
approaches coupled to machine learning offers exciting opportunities to advance understanding of state-specific 
brain chemistry.
Materials and Methods
Animals. Adult, male C57BL/6 J (B6, wild type) mice (25 to 30 g; n = 19) were used. All animal procedures 
and experimental protocols followed the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals70 and were approved by the University of Wisconsin-Madison licensing committee. Animal facilities 
were reviewed and approved by the institutional animal care and use committee (IACUC) of the University of 
Wisconsin-Madison and were inspected and accredited by association for assessment and accreditation of labo-
ratory animal care (AAALAC).
Stereotaxic Surgery. Implantation of recording electrodes and microdialysis guide tubes was performed 
under isoflurane anesthesia (2% for induction, 1 to 1.5% for maintenance). Each mouse was implanted with two 
microdialysis guide cannulae (Fig. 1a). One cannula was aimed for the left medial prefrontal cortex (mPFC) using 
stereotaxic coordinates Bregma AP + 1.94, ML − 0.371. A second cannula was aimed for the right primary motor 
cortex (M1) with stereotaxic coordinates of AP + 1.5, ML + 272. For electroencephalographic (EEG) recordings, 
screw electrodes were implanted over left and right parietal cortex (AP − 2, ML +/− 2) and cerebellum (refer-
ence electrode). To record the electromyogram (EMG), two stainless steel wires were implanted into the nuchal 
muscles. Cannulae and electrodes were fixed to the skull with dental cement. After surgery, mice were individu-
ally housed in transparent Plexiglas cages. Environmental lighting provided a 12 h:12 h light/dark cycle (lights on 
at 8 am; 23 ± 1 °C) with food and water available ad libitum and replaced daily at 8 am. Approximately one week 
was allowed for recovery from surgery, and microdialysis experiments started only after the temporal organiza-
tion of sleep and wakefulness had normalized.
EEG and EMG Recordings for Quantifying States of Sleep and Wakefulness. For one week after 
surgery the mice were conditioned for sleep studies by connecting them via a flexible cable to a multichannel neu-
rophysiology recording and stimulation system that enabled EEG and EMG recordings (Fig. 1b) (Tucker-Davis 
Technologies Inc.). EEG and EMG signals were amplified and filtered as follows: EEG, high-pass filter at 0.1 Hz; 
low-pass filter at 100 Hz; EMG, high-pass filter at 10 Hz; low-pass filter at 100 Hz). All signals were sampled and 
stored at 256 Hz. States of sleep and wakefulness were scored off-line in 4-sec epochs using standard criteria.
Microdialysis Experiments. The day before the experiment, each mouse was briefly anesthetized with iso-
flurane and the microdialysis probes (15 KDa pore size) were inserted into the guide cannulae23. Microdialysis 
probes in the mouse homologue of mPFC and M1 were connected to the microfluidic circuit (Fig. 1b) and per-
fused with artificial extracellular fluid (aECF) comprised of mM concentrations of: NaCl 147, KCl 2.7, CaCl2 
1.2, MgCl2 0.85. The microperfusion pump (CMA/400, CMA Microdialysis), maintained aECF flow rate of 
1.1 µL/min. Experiments were conducted from 7 am until 6 pm or from 7 pm until 6 am, during which time 
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microdialysis samples from each cortical probe were collected every 15 min in 250 μL plastic vials (ESA, PN 
70–1695; ESA, Inc.). At the conclusion of each dialysis experiment, microdialysis sites were histologically con-
firmed to be located in the targeted brain area. Dialysis samples were stored at −80 °C until they were shipped to 
the University of Tennessee to be analyzed using Ultra Performance Liquid Chromatography-High Resolution 
Mass Spectrometry (UPLC-HRMS) and an established metabolomics method73. At the University of Tennessee 
samples were also maintained at −80 °C until they were thawed and measured.
Experimental Groups. Three different experimental groups were used (Fig. 1c). Mice are polyphasic, and 
thus can spend a substantial amount of time awake during their major sleep phase (day) and asleep at night, dur-
ing their major wake phase. To standardize and consolidate sleep and wake episodes mice were first placed on a 
slowly rotating treadmill that kept them awake for 2 h. Dialysis samples collected during the second hour served 
as baseline measurements for standardizing the samples collected during the following 9 h of the light period (first 
two groups) or of the dark period (third group). Figure 1d shows the percent of time mice in each of the three 
groups spent awake during each 15-min sampling bin.
Group 1: Sleep for 6 h followed by enforced wakefulness on treadmill for 3 h (S6-EW3; n = 7 mice). At 7 am, one 
hour before lights-on, each mouse was placed on a slowly moving treadmill (speed ≈ 0.7 cm/sec) and the flow 
for microdialysis probe was activated (1.1 µL/min). The mouse was awake while slowly moving on the platform, 
and five microdialysis samples were collected during the second hour to serve as reference. The mouse was then 
returned to its cage and allowed to sleep for 6 h. After ad libitum sleep, at 3 pm the mouse was placed back on the 
slowly moving treadmill for 3 h, to obtain EEG recordings and microdialysis samples during a “standardized” 
period of wakefulness, in which the mouse behavior was as homogenous as possible.
Group 2: Enforced wake for 6 h followed by sleep for 3 h (EW6-S3; n = 6 mice). As described above, mice were 
placed on the slowly moving treadmill starting at 7 am and the second hour was used as reference. Mice were 
then returned to their cage and kept awake by exposure to novel objects for 6 h, followed at 3 pm by ad libitum 
sleep for 3 h.
Group 3: Spontaneous wakefulness for 6 h followed by enforced wakefulness on treadmill for 3 h (SW6-EW3; n = 6 
mice). Mice were placed on the slowly moving treadmill for 2 h starting at 7 pm, one hour before lights-off, and 
the second hour served as reference. At 9 pm mice returned to their cage and as expected, were spontaneously 
awake for most of the time. A novel object was placed in the cage every ~30 min to help maintain a sustained 
period of wake, but if the mouse slept, it was allowed to do so and microdialysis samples were not used for subse-
quent analyses. At 3 am mice were placed back on the treadmill for 3 h.
Untargeted metabolomics using UPLC-HRMS. The present study used an untargeted approach to pro-
file the metabolome of each dialysis sample. This technique provided information both for metabolites of known 
structure, which were identified as outlined below, and for metabolites with undetermined structure. Prior to 
untargeted analyses, a 15-μL aliquot of each microdialysis sample was diluted to 50 μL of total volume using 
Ringer’s solution. Instrumentation for untargeted metabolomics analysis included an Ultimate 3000 LC pump in 
line with an Exactive Plus Orbitrap™ mass spectrometer (Thermo Scientific). Ultra-performance liquid chroma-
tography (UPLC) was accomplished under previously established chromatography74 using a Synergi Hydro-RP 
column (100 mm × 2.1 mm, 2.5 μm, 100 Å). Metabolites were detected using high-resolution mass spectrometry 
(HRMS) in negative mode with an electrospray ionization (ESI) source.
Following detection, raw data were compiled using the Metabolomic Analysis and Visualization Engine 
(MAVEN) software package75. Known metabolites were selected from a pre-existing list of ~300 compounds 
based on exact mass and previously determined retention times73. Metabolite selection resulted in the reliable 
identification of more than 40 small molecules in more than 80% of subjects; Group 1 (31 ± 16, mean ± SD), 
Group 2 (47 ± 8), and Group 3 (45 ± 5). Additionally, MAVEN enabled the extraction of all spectral features 
detected during analysis. Each spectral feature refers to a potential metabolite with an exact parent mass detected 
at a specific retention time. After removal of “known” metabolites and carbon-13 isomers, the remaining spectral 
features were classified as “unknown”. Total unknown features: Group 1 (2436 ± 850, mean ± SD; range, 998–
3755), Group 2 (2388 ± 1529; range, 388–5016), and Group 3 (2297 ± 846; range, 947–2899).
Classification and Statistical Analysis. Pre-processing. To promote generalizability of the results, the 
analysis was restricted to metabolites that were observed at least in 3 mice per treatment condition. This selection 
criterion was applied separately to each brain region and provided a list of 33 known metabolites common to 
both regions (mPFC and M1), and 3 metabolites that were unique to mPFC (36 metabolites total; Fig. 2). Raw ion 
intensities were standardized into z-scores using the means and standard deviations estimated from the baseline 
samples; note that baseline corrections were performed separately for each mouse, brain region and metabolite 
combination. Next, outliers were detected and removed from the data set; an observation was classified as an 
outlier if its z-score was more than 5 times greater than all other observations for the mouse/brain region/metab-
olite. In total, 13 out of 34302 observations (less than 0.04%) were classified as outliers. The observations were 
then coarse-grained to a time-scale of 1 hour (e.g., averaging 4 consecutive values from the 15-min samples), 
reducing the data set to 9 time-points. This served to reduce the variability in the data, as well as the number of 
missing data points. Missing data occurred when a metabolite was not detected in a microdialysis sample, when 
data were omitted due to a mouse being in the “wrong” behavioral state (for example, for a mouse in Group 1, a 
15-min sample during the first 6 hours was discarded if during that time interval the mouse had been more than 
50% of time awake rather than asleep), or when an observation was removed as an outlier. After coarse-graining, 
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the remaining missing data were imputed in the following manner: 1) for metabolites that were completely absent 
from a sample, missing values were estimated by the mean z-score for that metabolite/time point across all other 
mice in the same experimental condition; 2) the remaining missing data points were estimated using the k = 2 
nearest neighbors algorithm and averaging the observations for the two nearest time-points within the corre-
sponding mouse/metabolite/brain region.
In total 1960 missing observations were interpolated to complete the data set (199 completely missing metab-
olites with 9 time-points each; 156 individual missing observations and 13 outliers), making up 16.6% of the total 
data set. It is worth noting that three mice (all in the S6-EW3 condition) contributed 66% of the missing values 
(1299 out of 1960). On further inspection, no technical reason why the samples from these three mice should be 
excluded was found. Furthermore, removing these mice from the analysis made no qualitative differences to the 
results. We thus conclude that the bias for missing data to be in the S6-EW3 condition does not adversely affect 
the outcomes of the analysis, and all results are reported from the fully imputed data set.
The unknown spectral features were clustered to determine whether the same peak was identified across mul-
tiple samples. Two observations were considered to measure the same unknown feature if their masses differed 
by less than 0.0014 and the retention times differed by less than 0.3. After clustering the features, we then applied 
the same preprocessing pipeline as described above for the known metabolites, resulting in a list of 39 unknown 
features (33 common to both mPFC and M1, and 3 unique features in each region).
Linear Mixed Effects Model. In order to determine whether there were statistically significant effects of prior 
treatment conditions and time on levels of measured analytes data were analyzed using LME models76,77. LME 
models are one of the few statistical techniques that are appropriate for analyzing repeated measures data, as 
most traditional parametric statistical techniques rely on the assumption of independence between data points. 
The other common approach for this type of data is a repeated measures ANOVA, but the LME analysis is more 
flexible with respect to missing data, and our analysis included many missing values, due to the absence of a 
compound at a specific time point or brain region, and/or due to a mouse that did not meet the criteria for sleep 
or wakefulness at a given time point.
A linear mixed effect model includes both “fixed” and “random” effects, allowing to determine the effect of a 
variable with a fixed number of states (in our case, the 3 behavioral conditions of either sleep, spontaneous wake-
fulness or enforced wakefulness), while simultaneously controlling for the effects of another variable for which 
only a random sample of possible values are observed (e.g., a random sample of mice). A mixed effect model has 
the form
Y b X b Zi t i
p
P
p i t p
q
Q
i q i t q i t, 0 ,0
1
, ,
1
, , , ,∑ ∑β β= + + + +
= =
where,
σ∼b N(0, ),i q q,
2
and
 σ∼ .N(0, )i t,
2
In this model, Yi,t is the response variable, in our case the compound sample of the ith mouse at the tth time point. 
The residuals ϵi,t were assumed to be independent and normally distributed with constant variance. To ensure 
the assumptions of normality and constant variance were satisfied, response values for some compounds were 
transformed using a log or square root transformation. The βp values correspond to the fixed effects in the model 
and bi,q are the random effects, which are assumed to be normally distributed, with mean zero and constant vari-
ance. The design matrices X and Z contain the values for each fixed and random explanatory variable respectively. 
Parameters for the LME models were estimated numerically using the lme4 library for the R software package78.
A model selection procedure was applied separately for each metabolite. Following79, we included as many 
random effects terms in each model as the data supported; when the variance of a random effect went to zero or 
two random effects became perfectly correlated then the model was over parameterized. Once the structure of 
the random effects was determined, the Akaike Information Criterion80 was used to select the set of fixed effects 
in the model.
Statistical analysis of the LMEs was performed using likelihood ratio tests, comparing the full model as iden-
tified by the model selection procedure with a reduced model with the effect of condition removed. Depending 
on the specific form of the fixed effects in the model, this could result in a test for a main effect of condition or a 
condition x time interaction.
An additional LME model was fit for each compound to study the concentration of metabolites at different 
time windows during the sleep experiments. Specifically, we defined a ‘sleep condition’ as a categorical fixed effect 
with 3 levels: “early” (first 3 h of the S6 experiment), “late” (last 3 h of the S6 experiment), and “recovery” (3 h 
of sleep after the EW6 experiment). The LME models were fit with sleep condition as a categorical fixed effect, 
time as a linear fixed effect, and mouse as a random effect. A likelihood ratio test was used to test for a significant 
interaction between sleep condition and time, that is, whether the trend for metabolite concentration (increasing, 
decreasing, constant) was different during the different sleep conditions.
Classification analyses. Multiple classification models were employed to determine whether microdialysis meas-
urements could be used to accurately classify behavioral state sampling epochs as sleep, spontaneous wakefulness 
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or enforced wakefulness. These analyses used the combined data from the mPFC and M1 brain regions to clas-
sify the metabolic profiles of sleep (S6), spontaneous wakefulness (SW6) and enforced wakefulness (EW6). One 
classification model employed was a partial least squares discriminant analysis (PLSDA), computed using the 
DiscriMiner package (https://www.rdocumentation.org/packages/DiscriMiner) in R, with figures generated 
using the ggbiplot package (https://www.rdocumentation.org/packages/ggbiplot).
A unique function of this technique is the feature classification model that produces a list of variable impor-
tance of projection (VIP) scores for each metabolite. As a sparse classification model, we considered logistic 
regression with an ℓ2 regularization penalty, implemented using the Python package scikit-learn. In problems 
with many more variables than observations, a sparse model prevents overfitting and improves prediction 
accuracy.
Prediction accuracy was assessed using a repeated 3-fold stratified cross-validation. Briefly, the population 
was divided into 3 groups, with the number of mice from each condition approximately equal for each group. 
Two of the groups were used to train the models (training set) and the remaining group was used to test the accu-
racy (test set). The process of dividing the mice into groups was repeated 100 times, and the prediction accuracy 
was estimated as the average across all repetitions. Significance testing for the classifiers was performed using a 
nonparametric permutation test. The condition labels for the mice were randomly permutated to remove any 
distinctions between the groups, and then the classifiers were reapplied, capturing the expected accuracy under 
the hypothesis of no differences. This method captures both the fact that chance levels of accuracy are 50% (33% 
for 3-way classification) and the structure of the design matrix, i.e., the number of predictor variables compared 
to the number of observations. The structure of the design matrix is important to consider because with so many 
predictors, one might expect to do better than chance even in the absence of a true difference between groups.
Data availability. All relevant data are available from the authors upon request.
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